Evidence map›Paper›PMID 34759935›Full record

ArticleFrontiers in immunology2021

Vedolizumab for the Management of Refractory Behçet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease.

Marta Arbrile, Massimo Radin, Daniela Rossi, Elisa Menegatti, Simone Baldovino, Savino Sciascia, Dario Roccatello

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Management of Severe Behçet's Disease.Current rheumatology reports · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Marta ArbrileCenter of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, Complex Structure with University Management (SCDU) Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy.
Massimo RadinCenter of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, Complex Structure with University Management (SCDU) Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy.
Daniela RossiCenter of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, Complex Structure with University Management (SCDU) Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy.
Elisa MenegattiCenter of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, Complex Structure with University Management (SCDU) Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy.
Simone BaldovinoCenter of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, Complex Structure with University Management (SCDU) Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy.
Savino SciasciaCenter of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, Complex Structure with University Management (SCDU) Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy.
Dario RoccatelloCenter of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, Complex Structure with University Management (SCDU) Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy.
Ospedale San Giovanni Bosco · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: When treating Behçet's disease (BD), anti-tumor necrosis factor (TNF)-α agents have become a second-line therapy when conventional immunosuppressive drugs have failed. However, in the case of failure of treatment with anti-TNFα drugs, further options are limited. Based on previous reports of the efficacy of vedolizumab (VDZ) in inflammatory bowel diseases, we decided to administer VDZ to treat a patient with intestinal BD. Methods: We present the case of a 49-year-old female patient with BD. Her clinical manifestations included erythema nodosum, oro-genital ulcers, positive Pathergy test, positive HLA-B51, and biopsy-proven intestinal BD. The patient was unsuccessfully treated with conventional immunosuppressive and several biological agents. Results: Treatment with VDZ was started intravenously at a dose of 300 mg at 0, 2, and 6 weeks and then every 4 weeks. After the second dose of VDZ, the patient reported a marked improvement of intestinal BD and a concomitant amelioration of arthralgia, erythema nodosum lesions and aphthosis. Clinical remission was achieved at 6 months after starting VDZ. Conclusion: VDZ might represent a valid option to treat patients with BD who are non-responsive to standard treatments or anti-TNFα agents, particularly, those cases with intestinal involvement.

Indexed as

Antibodies, Monoclonal, HumanizedBehcet SyndromeDrug ResistanceErythema NodosumFemaleHumansInjections, IntravenousMiddle AgedRemission InductionTreatment OutcomeAntibodies, Monoclonal, HumanizedvedolizumabBehçet diseasebiological drugbiological therapyintestinal Behçetvedolizumab

Identifiers

PMID34759935
PMCPMC8573273
OpenAlexW3208036203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.